On December 11, 2024, a leading domestic biotechnology company announced that they had achieved a major breakthrough in the research and development of recombinant human serum albumin (rHSA). This accomplishment marks an important step forward for China in the field of biomedicine and also has a profound impact on the global healthcare industry.
Recombinant human serum albumin is a kind of human serum albumin produced through genetic engineering technology. Serum albumin is one of the main protein components in human plasma, accounting for approximately 50% to 60% of the total plasma protein. It plays a crucial role in maintaining plasma colloid osmotic pressure and transporting various substances (such as hormones, vitamins, minerals, and drugs). In addition, albumin also has multiple physiological functions, including providing nutrition, detoxification, and regulating immune functions.
For a long time, human serum albumin has been mainly extracted from human plasma. However, this method has many limitations, such as limited sources of raw materials, the potential risk of viral contamination, and the complexity of the extraction process. With the continuous increase in medical needs, the supply of natural human serum albumin is far from meeting clinical requirements. The emergence of recombinant human serum albumin has provided an effective way to solve this problem.
According to the person in charge of the biotechnology company, they used advanced genetic engineering technology to introduce the human serum albumin gene into specific host cells (such as yeast or mammalian cells) and produced high-purity and high-activity recombinant human serum albumin through large-scale cell culture. This technology not only improves production efficiency but also significantly reduces production costs and the risk of viral contamination.
After undergoing strict clinical trials, the recombinant human serum albumin developed this time has shown biological functions and safety similar to those of natural serum albumin. This means that in the future, recombinant human serum albumin can be widely used in clinical treatment, such as treating ascites or edema caused by liver cirrhosis, nephrotic syndrome, hypoproteinemia, etc., and being used for acute albumin loss caused by burns, trauma, etc. In addition, recombinant human serum albumin can also be used as a plasma volume expander in emergency situations such as surgeries and shock.
Industry insiders pointed out that the successful research and development of recombinant human serum albumin not only alleviates the shortage of albumin supply but also promotes the innovative development of the biomedical industry. With the continuous maturity of the technology and further reduction of costs, recombinant human serum albumin is expected to be widely used worldwide in the future, bringing benefits to more patients.
The biotechnology company stated that they will continue to increase investment in research and development, promote the industrialization process of recombinant human serum albumin, and explore its applications in more fields. At the same time, they will also cooperate with domestic and foreign medical institutions and research institutions to further verify and improve the clinical application plan of recombinant human serum albumin.
Post time: Dec-11-2024
